首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

1956821

細胞及基因治療製造服務市場分析及預測（至2035年）：類型、產品類型、服務、技術、組件、應用、製程、最終用戶、階段

Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Stage

出版日期: 2026年02月11日 | 出版商:

Global Insight Services | 英文 330 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

細胞和基因治療生產服務市場預計將從2024年的148億美元成長到2034年的517億美元，複合年成長率約為13.6%。該市場涵蓋專門從事細胞和基因治療生產的設施和服務，包括製程開發、品管和法規遵循。推動該市場成長的因素包括個人化醫療的進步、對創新治療方法日益成長的需求以及對專業生產能力的需求。為了滿足對複雜生物生物製藥日益成長的需求，該行業高度重視擴充性、成本效益和技術創新。

細胞和基因治療生產服務市場正經歷強勁成長，這主要得益於個人化醫療和再生醫學領域的創新。細胞治療領域成長最為迅猛，自體細胞療法憑藉其個人化治療方案和潛在的高療效而主導。在該領域，CAR-T細胞療法因其在治療某些癌症方面的成功案例而備受關注。基因療法緊隨其後，體內基因療法也展現出良好的發展前景，其優勢在於可直接給藥，並有望用於治療遺傳性疾病。體外基因療法則是第三，其特徵是在細胞重新註入患者體內之前，能夠精確控制基因修飾。由於生產流程外包的日益普及，專注於這些治療方法的合約開發和生產組織（CDMO）的重要性日益凸顯。市場對可擴展生產解決方案和先進生物製程技術的需求不斷成長，反映出產業對效率和成本效益的迫切需求。這些趨勢凸顯了市場的動態發展和巨大的潛在盈利機會。

市場區隔
類型	異體移植、自體移植、病毒載體、非病毒載體、質體DNA、細胞株、基因編輯
產品	細胞治療產品、基因治療產品、病毒載體產品、非病毒載體產品、質體DNA產品
服務	製程開發、分析測試、品管、法規支援、供應鏈管理
科技	CRISPR、TALEN、ZFN、慢病毒載體、AAV載體、逆轉錄病毒載體
成分	試劑、培養基、緩衝液、無血清培養基
應用領域	腫瘤科、心血管疾病科、神經系統疾病科、罕見疾病科、感染疾病
流程	上游工程、下游製程、填充和精加工
最終用戶	生物製藥公司、研究機構、受託研究機構
步	臨床前、臨床和商業化生產階段

策略定價和創新產品推出正在推動細胞和基因治療生產服務市場市場佔有率的動態變化。主要企業正利用先進技術提高生產效率並實施具有競爭力的定價策略。新型治療方法的推出正在改變整個產業，企業正專注於個人化和標靶治療。這種演變在醫療基礎設施發達的地區尤其顯著，加速了對最先進治療的需求。競爭基準分析揭示了激烈的市場競爭格局，老牌企業和新興企業都在爭奪主導。監管的影響至關重要，尤其是在北美和歐洲等地區，嚴格的標準正在影響企業的市場准入和擴大策略。企業正在大力投資合規和品質保證，以滿足這些監管要求。市場分析強調了策略夥伴關係關係和合作的重要性，這對於駕馭複雜的監管環境和實現永續成長至關重要。

主要趨勢和促進因素：

細胞和基因治療生產服務市場正經歷強勁成長，這主要得益於幾個關鍵趨勢和促進因素。其中一個顯著趨勢是人們對個人化醫療的需求日益成長，這推動了細胞和基因治療技術的進步。這一趨勢反映了治療領域向個人化治療的廣泛轉變，旨在滿足個別患者的需求，從而提高治療效果和療效。此外，生產流程的技術進步正在革新市場。自動化系統和一次性技術等創新正在提高效率和擴充性，降低生產成本，並加快產品上市速度。這些進步對於滿足日益成長的細胞和基因治療需求至關重要。監管支持和有利的政策也在推動市場成長。各國政府和監管機構透過簡化核准流程和提供研發獎勵，促進該領域的創新和投資。此外，生技公司和學術機構之間的合作正在加速新型治療方法的開發，以擴大市場潛力。最後，慢性病和遺傳性疾病的日益普遍也推動了對細胞和基因療法的需求。隨著人們對這些治療方法的認知不斷提高，對可靠的生產服務的需求也隨之成長，以確保這些療法的可用性和可及性。這些因素綜合起來，為市場的持續擴張奠定了基礎，為相關人員提供了盈利的機會。

市場規模及預測：依類型
- 同種異體移植
- 自體移植
- 病毒載體
- 非病毒載體
- 質體DNA
- 細胞株
- 基因編輯
市場規模及預測：依產品分類
- 細胞治療產品
- 基因治療產品
- 病毒載體產品
- 非病毒載體產品
- 質體DNA產物
市場規模及預測：依服務分類
- 製程開發
- 分析測試
- 品管
- 監管支持
- 供應鏈管理
市場規模及預測：依技術分類
- CRISPR
- TALEN
- ZFN
- 慢病毒載體
- AAV載體
- 逆轉錄病毒載體
市場規模及預測：依組件分類
- 試劑
- 媒體
- 緩衝
- 無血清培養基
市場規模及預測：依應用領域分類
- 腫瘤學
- 心血管疾病
- 神經系統疾病
- 罕見疾病
- 感染疾病
市場規模及預測：依製程分類
- 上游工程
- 下游工藝
- 填充/包裝過程
市場規模及預測：依最終用戶分類
- 生物製藥公司
- 研究所
- 合約研究機構
市場規模及預測：依階段分類
- 臨床前階段
- 臨床
- 商業的

第5章區域分析

北美洲
- 美國
- 加拿大
- 墨西哥
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲地區
亞太地區
- 中國
- 印度
- 韓國
- 日本
- 澳洲
- 台灣
- 亞太其他地區
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 義大利
- 其他歐洲地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 南非
- 撒哈拉以南非洲
- 其他中東和非洲地區

第6章市場策略

需求與供給差距分析
貿易和物流限制
價格、成本和利潤率趨勢
市場滲透率
消費者分析
法規概述

第7章競爭訊息

市場定位
市場占有率
競爭基準
主要企業的策略

第8章公司簡介

Wu Xi App Tec
Lonza
Catalent
Sartorius
Thermo Fisher Scientific
Charles River Laboratories
Parexel
Pall Corporation
Bio NTech
Fujifilm Diosynth Biotechnologies
Samsung Biologics
AGC Biologics
Cognate Bio Services
Oxford Biomedica
Miltenyi Biotec
Cell and Gene Therapy Catapult
Center for Breakthrough Medicines
Vineti
Bluebird Bio
Orchard Therapeutics

第9章：關於我們

簡介目錄

Product Code: GIS21083

Cell and Gene Therapy Manufacturing Services Market is anticipated to expand from $14.8 billion in 2024 to $51.7 billion by 2034, growing at a CAGR of approximately 13.6%. The Cell and Gene Therapy Manufacturing Services Market encompasses facilities and services dedicated to the production of cell and gene therapies, including process development, quality control, and regulatory compliance. This market is driven by advancements in personalized medicine, increasing demand for innovative therapies, and the need for specialized manufacturing capabilities. The sector emphasizes scalability, cost-efficiency, and technological innovation to meet the rising demand for complex biologics.

The Cell and Gene Therapy Manufacturing Services Market is experiencing robust growth, propelled by innovations in personalized medicine and regenerative therapies. The cell therapy segment is the top performer, with autologous cell therapies leading due to their personalized approach and potential for high efficacy. Within this segment, CAR-T cell therapies are particularly noteworthy, given their success in treating certain cancers. Gene therapy follows closely, with in vivo gene therapy showing promise due to its direct delivery method and potential for treating genetic disorders. The second highest performing segment is ex vivo gene therapy, which offers precise control over genetic modifications before reintroducing cells into the patient. Contract development and manufacturing organizations (CDMOs) specializing in these therapies are gaining traction, driven by the increasing outsourcing of manufacturing processes. The demand for scalable manufacturing solutions and advanced bioprocessing technologies is rising, reflecting the industry's need for efficiency and cost-effectiveness. These trends underscore the market's dynamic evolution and potential for lucrative opportunities.

Market Segmentation
Type	Allogeneic, Autologous, Viral Vectors, Non-viral Vectors, Plasmid DNA, Cell Lines, Gene Editing
Product	Cell Therapy Products, Gene Therapy Products, Viral Vector Products, Non-viral Vector Products, Plasmid DNA Products
Services	Process Development, Analytical Testing, Quality Control, Regulatory Support, Supply Chain Management
Technology	CRISPR, TALEN, ZFN, Lentiviral Vectors, AAV Vectors, Retroviral Vectors
Component	Reagents, Media, Buffers, Serum-Free Media
Application	Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases
Process	Upstream Processing, Downstream Processing, Fill and Finish
End User	Biopharmaceutical Companies, Research Institutes, Contract Research Organizations
Stage	Preclinical, Clinical, Commercial

The Cell and Gene Therapy Manufacturing Services Market is witnessing a dynamic shift in market share, driven by strategic pricing and innovative product launches. Key industry players are leveraging advanced technologies to enhance manufacturing efficiencies, thereby offering competitive pricing strategies. The introduction of novel therapies is reshaping the landscape, with companies focusing on personalized medicine and targeted treatments. This evolution is particularly pronounced in regions with robust healthcare infrastructure, where demand for cutting-edge therapies is accelerating. Competition benchmarking reveals a highly competitive environment, with established firms and emerging players vying for dominance. Regulatory influences play a pivotal role, particularly in regions like North America and Europe, where stringent standards impact market entry and expansion strategies. Companies are investing heavily in compliance and quality assurance to meet these regulatory demands. The market analysis underscores the importance of strategic partnerships and collaborations, which are essential for navigating the complex regulatory landscape and achieving sustainable growth.

Geographical Overview:

The Cell and Gene Therapy Manufacturing Services Market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, propelled by advanced healthcare infrastructure and substantial investments in biotechnology. The region's strong research and development capabilities further bolster its position as a market leader. Europe follows, with significant government support and a strong focus on innovative therapies, enhancing its market potential. In the Asia Pacific, the market is expanding rapidly. This growth is driven by increasing healthcare expenditures and technological advancements in biotechnology. Countries like China and India are emerging as key players due to their large patient populations and favorable regulatory environments. Latin America and the Middle East & Africa are also showing promising growth. Latin America benefits from rising investments in healthcare infrastructure, while the Middle East & Africa are recognizing the potential of cell and gene therapies in addressing unmet medical needs.

Global tariffs and geopolitical risks are significantly influencing the Cell and Gene Therapy Manufacturing Services Market. In Japan and South Korea, trade tensions with the US and China are prompting increased investment in domestic biotech capabilities to mitigate reliance on foreign inputs. China is accelerating its push for self-sufficiency in biopharmaceuticals, while Taiwan leverages its advanced manufacturing prowess to strengthen its position as a key player. The parent market is experiencing robust growth due to rising demand for advanced therapeutics. By 2035, the market is expected to expand significantly, driven by innovation and strategic regional collaborations. Middle East conflicts could disrupt global supply chains, affecting energy prices and manufacturing costs, thereby impacting the biomanufacturing sector's growth trajectory.

Key Trends and Drivers:

The Cell and Gene Therapy Manufacturing Services Market is experiencing robust growth driven by several key trends and drivers. A significant trend is the increasing demand for personalized medicine, which is propelling advancements in cell and gene therapies. This trend reflects a broader shift towards tailored treatments that cater to individual patient needs, enhancing therapeutic efficacy and outcomes. Additionally, technological advancements in manufacturing processes are revolutionizing the market. Innovations such as automated systems and single-use technologies are improving efficiency and scalability, reducing production costs, and accelerating time-to-market. These advancements are crucial for meeting the rising demand for cell and gene therapies. Regulatory support and favorable policies are also driving market growth. Governments and regulatory bodies are streamlining approval processes and providing incentives for research and development, fostering innovation and investment in this sector. Moreover, collaborations between biotech companies and academic institutions are accelerating the development of novel therapies, expanding the market's potential. Finally, the increasing prevalence of chronic diseases and genetic disorders is fueling demand for cell and gene therapies. As awareness of these therapies grows, so does the need for reliable manufacturing services to ensure their availability and accessibility. This confluence of factors positions the market for sustained expansion and offers lucrative opportunities for stakeholders.

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Component
2.6 Key Market Highlights by Application
2.7 Key Market Highlights by Process
2.8 Key Market Highlights by End User
2.9 Key Market Highlights by Stage

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Allogeneic
- 4.1.2 Autologous
- 4.1.3 Viral Vectors
- 4.1.4 Non-viral Vectors
- 4.1.5 Plasmid DNA
- 4.1.6 Cell Lines
- 4.1.7 Gene Editing
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Cell Therapy Products
- 4.2.2 Gene Therapy Products
- 4.2.3 Viral Vector Products
- 4.2.4 Non-viral Vector Products
- 4.2.5 Plasmid DNA Products
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Process Development
- 4.3.2 Analytical Testing
- 4.3.3 Quality Control
- 4.3.4 Regulatory Support
- 4.3.5 Supply Chain Management
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 CRISPR
- 4.4.2 TALEN
- 4.4.3 ZFN
- 4.4.4 Lentiviral Vectors
- 4.4.5 AAV Vectors
- 4.4.6 Retroviral Vectors
4.5 Market Size & Forecast by Component (2020-2035)
- 4.5.1 Reagents
- 4.5.2 Media
- 4.5.3 Buffers
- 4.5.4 Serum-Free Media
4.6 Market Size & Forecast by Application (2020-2035)
- 4.6.1 Oncology
- 4.6.2 Cardiovascular Diseases
- 4.6.3 Neurological Disorders
- 4.6.4 Rare Diseases
- 4.6.5 Infectious Diseases
4.7 Market Size & Forecast by Process (2020-2035)
- 4.7.1 Upstream Processing
- 4.7.2 Downstream Processing
- 4.7.3 Fill and Finish
4.8 Market Size & Forecast by End User (2020-2035)
- 4.8.1 Biopharmaceutical Companies
- 4.8.2 Research Institutes
- 4.8.3 Contract Research Organizations
4.9 Market Size & Forecast by Stage (2020-2035)
- 4.9.1 Preclinical
- 4.9.2 Clinical
- 4.9.3 Commercial

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Component
  - 5.2.1.6 Application
  - 5.2.1.7 Process
  - 5.2.1.8 End User
  - 5.2.1.9 Stage
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Component
  - 5.2.2.6 Application
  - 5.2.2.7 Process
  - 5.2.2.8 End User
  - 5.2.2.9 Stage
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Component
  - 5.2.3.6 Application
  - 5.2.3.7 Process
  - 5.2.3.8 End User
  - 5.2.3.9 Stage
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Component
  - 5.3.1.6 Application
  - 5.3.1.7 Process
  - 5.3.1.8 End User
  - 5.3.1.9 Stage
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Component
  - 5.3.2.6 Application
  - 5.3.2.7 Process
  - 5.3.2.8 End User
  - 5.3.2.9 Stage
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Component
  - 5.3.3.6 Application
  - 5.3.3.7 Process
  - 5.3.3.8 End User
  - 5.3.3.9 Stage
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Component
  - 5.4.1.6 Application
  - 5.4.1.7 Process
  - 5.4.1.8 End User
  - 5.4.1.9 Stage
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Component
  - 5.4.2.6 Application
  - 5.4.2.7 Process
  - 5.4.2.8 End User
  - 5.4.2.9 Stage
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Component
  - 5.4.3.6 Application
  - 5.4.3.7 Process
  - 5.4.3.8 End User
  - 5.4.3.9 Stage
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Component
  - 5.4.4.6 Application
  - 5.4.4.7 Process
  - 5.4.4.8 End User
  - 5.4.4.9 Stage
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Component
  - 5.4.5.6 Application
  - 5.4.5.7 Process
  - 5.4.5.8 End User
  - 5.4.5.9 Stage
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Component
  - 5.4.6.6 Application
  - 5.4.6.7 Process
  - 5.4.6.8 End User
  - 5.4.6.9 Stage
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Component
  - 5.4.7.6 Application
  - 5.4.7.7 Process
  - 5.4.7.8 End User
  - 5.4.7.9 Stage
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Component
  - 5.5.1.6 Application
  - 5.5.1.7 Process
  - 5.5.1.8 End User
  - 5.5.1.9 Stage
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Component
  - 5.5.2.6 Application
  - 5.5.2.7 Process
  - 5.5.2.8 End User
  - 5.5.2.9 Stage
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Component
  - 5.5.3.6 Application
  - 5.5.3.7 Process
  - 5.5.3.8 End User
  - 5.5.3.9 Stage
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Component
  - 5.5.4.6 Application
  - 5.5.4.7 Process
  - 5.5.4.8 End User
  - 5.5.4.9 Stage
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Component
  - 5.5.5.6 Application
  - 5.5.5.7 Process
  - 5.5.5.8 End User
  - 5.5.5.9 Stage
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Component
  - 5.5.6.6 Application
  - 5.5.6.7 Process
  - 5.5.6.8 End User
  - 5.5.6.9 Stage
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Component
  - 5.6.1.6 Application
  - 5.6.1.7 Process
  - 5.6.1.8 End User
  - 5.6.1.9 Stage
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Component
  - 5.6.2.6 Application
  - 5.6.2.7 Process
  - 5.6.2.8 End User
  - 5.6.2.9 Stage
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Component
  - 5.6.3.6 Application
  - 5.6.3.7 Process
  - 5.6.3.8 End User
  - 5.6.3.9 Stage
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Component
  - 5.6.4.6 Application
  - 5.6.4.7 Process
  - 5.6.4.8 End User
  - 5.6.4.9 Stage
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Component
  - 5.6.5.6 Application
  - 5.6.5.7 Process
  - 5.6.5.8 End User
  - 5.6.5.9 Stage

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Wu Xi App Tec
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Lonza
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Catalent
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Sartorius
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Thermo Fisher Scientific
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Charles River Laboratories
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Parexel
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Pall Corporation
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Bio NTech
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Fujifilm Diosynth Biotechnologies
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Samsung Biologics
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 AGC Biologics
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Cognate Bio Services
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Oxford Biomedica
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Miltenyi Biotec
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Cell and Gene Therapy Catapult
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Center for Breakthrough Medicines
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Vineti
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Bluebird Bio
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Orchard Therapeutics
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis